PARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7. [PDF]
NAR CancerColón-Ríos DA +5 more
europepmc +1 more source
Efficacy at a cost?-quality of life implications of PARP inhibition in the homologus recombination repair (HRR) cohort of TALAPRO-2. [PDF]
Transl Androl UrolEsteban-Villarrubia J, Castro E.
europepmc +1 more source
Interplay Between Poly(ADP-ribosyl)ation and Specific Inner Cellular Events That Suggest Combination Strategies for Overcoming PARP Inhibitor Resistance. [PDF]
PharmaceuticsXu L +9 more
europepmc +1 more source
Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis [PDF]
Di Maio, Massimo
core +1 more source
Targeting fatty acid synthase to overcome PARP inhibitor resistance and to create an artificial synthetic lethality for triple-negative breast cancer. [PDF]
Genes DisJosephraj S +5 more
europepmc +1 more source
Population pharmacokinetic analyses for talazoparib (TALA) in cancer patients
Annals of Oncology, 2018 Y. Yu, C. Durairaj, H. Shi, D.D. Wang
openaire +1 more source
Incidentally Detected Ductal Adenocarcinoma Presenting With Isolated Pulmonary Metastasis and a BRCA2 Mutation. [PDF]
IJU Case RepKarasawa H +6 more
europepmc +1 more source
The Impact of Novel Therapies on Quality-of-Life in Triple-Negative Breast Cancer: A Systematic Review of Clinical Trials. [PDF]
Cancers (Basel)Kamau B, Shulimovich M, Samridhi S.
europepmc +1 more source
PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cells. [PDF]
Sci RepSuresh S, McPherson L, Ford JM.
europepmc +1 more source
Homologous Repair-Deficient Pancreatic Cancer: Refined Targeting of DNA Damage Response is an Effective Therapeutic Strategy. [PDF]
United European Gastroenterol JBeutel AK +9 more
europepmc +1 more source